津药达仁堂速效救心丸启动国家科技重大专项研究

Core Insights - The 2025 Cardiovascular Health Conference was held in Beijing, attracting nearly 20,000 participants, including leading experts in the cardiovascular field, to discuss public heart health [1][3] - A significant national scientific project, focusing on the "Rapid Rescue Heart Pill" for treating coronary microvascular diseases, was launched during the conference [1][3] Group 1: Clinical Challenges and Research Focus - Coronary microvascular disease is a critical challenge in treating coronary heart disease, with over 30% of patients experiencing inadequate myocardial perfusion despite successful PCI surgery [3] - The new national project aims to address the complexities of microcirculation, shifting clinical focus from merely opening large blood vessels to a dual protection model that includes both large vessels and microcirculation [3][4] Group 2: Integration of Traditional and Modern Medicine - The project will utilize traditional Chinese medicine's holistic approach alongside modern technologies like big data and artificial intelligence to create a dynamic and precise diagnostic and treatment paradigm [4] - The study will center on the "Rapid Rescue Heart Pill," collaborating with top institutions to conduct large-scale, multi-center clinical research adhering to international standards [4][6] Group 3: Strategic Importance for the Company - The involvement in this national project is strategically significant for the company, aiming to meet unmet clinical needs and provide evidence-based treatment options for patients suffering from angina post-PCI [6][8] - The company plans to leverage a rigorous quality control system to ensure the consistency and traceability of trial medications, aiming to clarify the mechanism and clinical value of the "Rapid Rescue Heart Pill" [8] - This initiative represents a key action for the company in implementing the "Healthy China 2030" plan and marks a transition from traditional manufacturing to technology-driven health management [8]